NIKKEI 225
37,613.43 -15.05 (-0.04%) HANG SENG
17,284.54 +83.27 (+0.48%) CRUDE OIL
83.89 +0.32 (+0.38%) GOLD FUTURES
2,341.00 -1.50 (-0.06%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,352.65 -319.79 (-0.62%)
Tarsus Pharmaceuticals, Inc. (TARS)
After hours:
- GlobeNewswire
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP. Tarsus has elected to draw $75 million on the closing date, April 19, 2024, with the remaining $125 million of committed capital avai
- Simply Wall St.
Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%
Insiders who bought Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) stock lover the last 12 months are probably not as...
- Zacks
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 47.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
